Cardurion Pharmaceuticals
PrivateLast Round
Series B
Jul 16, 2024
Total Funding Raised
$631.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Cardurion Pharmaceuticals is a biotechnology company that develops innovative cardiovascular therapeutics aimed at treating heart diseases and preventing related complications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cardurion Pharmaceuticals Comparables
Compare Cardurion Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kardigan | 79% | |
| AnaCardio | 77% | |
| Windtree Therapeutics, Inc. | 77% |
For institutional investors. Book with your work email.
Cardurion Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 16, 2024 | ||||
| Series A Extension | Dec 30, 2022 | ||||
| Private Equity | Oct 27, 2021 | ||||
| Series A | Nov 20, 2019 | ||||
| Seed | Aug 3, 2017 | ||||
Seed | Apr 4, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cardurion Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Owl Rock Capital Group | Series B |
| Bain Capital Life Sciences | Series B, Private Equity |
| Farallon Capital Management | Series B |
| GV | Series B |
| Digitalis Ventures | Series B |
| New Enterprise Associates | Series B |
| Millennium Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 32% MoM, reaching 4.1K.
- Jul 26, 2026
Monthly visitors increased 119% to 3.1K.
For institutional investors. Book with your work email.
Cardurion Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cardurion Pharmaceuticals's valuation, stock price, and market status.
Is Cardurion Pharmaceuticals a public or private company?
Cardurion Pharmaceuticals is a private company.
What is the current stock price of Cardurion Pharmaceuticals?
Cardurion Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Cardurion Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cardurion Pharmaceuticals worth (valuation)?
Valuation information for Cardurion Pharmaceuticals is not publicly available.
Can I buy Cardurion Pharmaceuticals stock?
Cardurion Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cardurion Pharmaceuticals's last funding round?
Cardurion Pharmaceuticals's most recent funding round was Series B on July 16, 2024.
Who are the main investors in Cardurion Pharmaceuticals?
Key investors in Cardurion Pharmaceuticals include Bain Capital Life Sciences, Bain Capital Private Equity, Bain Capital, LP, Polaris Partners, Ascenta Capital.
Will Cardurion Pharmaceuticals IPO soon?
No public IPO plans have been announced for Cardurion Pharmaceuticals.
How can I track Cardurion Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Cardurion Pharmaceuticals's shares on secondary markets.